Report error Found 1268 Enz. Inhib. hit(s) with Target = 'Nucleotide-binding oligomerization domain-containing protein 2'
TargetNucleotide-binding oligomerization domain-containing protein 2 (NOD2)(Human)
Odyssey Therapeutics
US Patent
Odyssey Therapeutics
US Patent
Affinity DataIC50: 0.100nMAssay Description:Biochemical JAK and Off-Target Kinase Assays. A panel of four LanthaScreen JAK biochemical assays (JAK1, 2, 3 and Tyk2) were carried in a common kin...More data for this Ligand-Target Pair
TargetNucleotide-binding oligomerization domain-containing protein 2 (NOD2)(Human)
Odyssey Therapeutics
US Patent
Odyssey Therapeutics
US Patent
Affinity DataIC50: 0.100nMAssay Description:Biochemical JAK and Off-Target Kinase Assays. A panel of four LanthaScreen JAK biochemical assays (JAK1, 2, 3 and Tyk2) were carried in a common kin...More data for this Ligand-Target Pair
TargetNucleotide-binding oligomerization domain-containing protein 2 (NOD2)(Human)
Odyssey Therapeutics
US Patent
Odyssey Therapeutics
US Patent
Affinity DataIC50: 0.100nMAssay Description:Biochemical JAK and Off-Target Kinase Assays. A panel of four LanthaScreen JAK biochemical assays (JAK1, 2, 3 and Tyk2) were carried in a common kin...More data for this Ligand-Target Pair
TargetNucleotide-binding oligomerization domain-containing protein 2 (NOD2)(Human)
Odyssey Therapeutics
US Patent
Odyssey Therapeutics
US Patent
Affinity DataIC50: 0.100nMAssay Description:Biochemical JAK and Off-Target Kinase Assays. A panel of four LanthaScreen JAK biochemical assays (JAK1, 2, 3 and Tyk2) were carried in a common kin...More data for this Ligand-Target Pair
TargetNucleotide-binding oligomerization domain-containing protein 2 (NOD2)(Human)
Odyssey Therapeutics
US Patent
Odyssey Therapeutics
US Patent
Affinity DataIC50: 0.200nMAssay Description:Biochemical JAK and Off-Target Kinase Assays. A panel of four LanthaScreen JAK biochemical assays (JAK1, 2, 3 and Tyk2) were carried in a common kin...More data for this Ligand-Target Pair
TargetNucleotide-binding oligomerization domain-containing protein 2 (NOD2)(Human)
Odyssey Therapeutics
US Patent
Odyssey Therapeutics
US Patent
Affinity DataIC50: 0.200nMAssay Description:Compounds were added to a 384-well plate. Reaction mixtures contained 10 mM HEPES, pH 7.4, 10 mM MgCl2, 0.01% BSA, 0.0005% Tween 20, 1 mM ATP and 1 &...More data for this Ligand-Target Pair
TargetNucleotide-binding oligomerization domain-containing protein 2 (NOD2)(Human)
Odyssey Therapeutics
US Patent
Odyssey Therapeutics
US Patent
Affinity DataIC50: 0.200nMAssay Description:Compounds were added to a 384-well plate. Reaction mixtures contained 10 mM HEPES, pH 7.4, 10 mM MgCl2, 0.01% BSA, 0.0005% Tween 20, 1 mM ATP and 1 &...More data for this Ligand-Target Pair
TargetNucleotide-binding oligomerization domain-containing protein 2 (NOD2)(Human)
Odyssey Therapeutics
US Patent
Odyssey Therapeutics
US Patent
Affinity DataIC50: 0.200nMAssay Description:Compounds were added to a 384-well plate. Reaction mixtures contained 10 mM HEPES, pH 7.4, 10 mM MgCl2, 0.01% BSA, 0.0005% Tween 20, 1 mM ATP and 1 &...More data for this Ligand-Target Pair
TargetNucleotide-binding oligomerization domain-containing protein 2 (NOD2)(Human)
Odyssey Therapeutics
US Patent
Odyssey Therapeutics
US Patent
Affinity DataIC50: 0.200nMAssay Description:Biochemical JAK and Off-Target Kinase Assays. A panel of four LanthaScreen JAK biochemical assays (JAK1, 2, 3 and Tyk2) were carried in a common kin...More data for this Ligand-Target Pair
TargetNucleotide-binding oligomerization domain-containing protein 2 (NOD2)(Human)
Odyssey Therapeutics
US Patent
Odyssey Therapeutics
US Patent
Affinity DataIC50: 0.200nMAssay Description:Compounds were added to a 384-well plate. Reaction mixtures contained 10 mM HEPES, pH 7.4, 10 mM MgCl2, 0.01% BSA, 0.0005% Tween 20, 1 mM ATP and 1 &...More data for this Ligand-Target Pair
TargetNucleotide-binding oligomerization domain-containing protein 2 (NOD2)(Human)
Odyssey Therapeutics
US Patent
Odyssey Therapeutics
US Patent
Affinity DataIC50: 0.200nMAssay Description:Biochemical JAK and Off-Target Kinase Assays. A panel of four LanthaScreen JAK biochemical assays (JAK1, 2, 3 and Tyk2) were carried in a common kin...More data for this Ligand-Target Pair
TargetNucleotide-binding oligomerization domain-containing protein 2 (NOD2)(Human)
Odyssey Therapeutics
US Patent
Odyssey Therapeutics
US Patent
Affinity DataIC50: 0.200nMAssay Description:Biochemical JAK and Off-Target Kinase Assays. A panel of four LanthaScreen JAK biochemical assays (JAK1, 2, 3 and Tyk2) were carried in a common kin...More data for this Ligand-Target Pair
TargetNucleotide-binding oligomerization domain-containing protein 2 (NOD2)(Human)
Odyssey Therapeutics
US Patent
Odyssey Therapeutics
US Patent
Affinity DataIC50: 0.200nMAssay Description:Compounds were added to a 384-well plate. Reaction mixtures contained 10 mM HEPES, pH 7.4, 10 mM MgCl2, 0.01% BSA, 0.0005% Tween 20, 1 mM ATP and 1 &...More data for this Ligand-Target Pair
TargetNucleotide-binding oligomerization domain-containing protein 2 (NOD2)(Human)
Odyssey Therapeutics
US Patent
Odyssey Therapeutics
US Patent
Affinity DataIC50: 0.200nMAssay Description:Biochemical JAK and Off-Target Kinase Assays. A panel of four LanthaScreen JAK biochemical assays (JAK1, 2, 3 and Tyk2) were carried in a common kin...More data for this Ligand-Target Pair
TargetNucleotide-binding oligomerization domain-containing protein 2 (NOD2)(Human)
Odyssey Therapeutics
US Patent
Odyssey Therapeutics
US Patent
Affinity DataIC50: 0.200nMAssay Description:Biochemical JAK and Off-Target Kinase Assays. A panel of four LanthaScreen JAK biochemical assays (JAK1, 2, 3 and Tyk2) were carried in a common kin...More data for this Ligand-Target Pair
TargetNucleotide-binding oligomerization domain-containing protein 2 (NOD2)(Human)
Odyssey Therapeutics
US Patent
Odyssey Therapeutics
US Patent
Affinity DataIC50: 0.300nMAssay Description:Biochemical JAK and Off-Target Kinase Assays. A panel of four LanthaScreen JAK biochemical assays (JAK1, 2, 3 and Tyk2) were carried in a common kin...More data for this Ligand-Target Pair
TargetNucleotide-binding oligomerization domain-containing protein 2 (NOD2)(Human)
Odyssey Therapeutics
US Patent
Odyssey Therapeutics
US Patent
Affinity DataIC50: 0.300nMAssay Description:Biochemical JAK and Off-Target Kinase Assays. A panel of four LanthaScreen JAK biochemical assays (JAK1, 2, 3 and Tyk2) were carried in a common kin...More data for this Ligand-Target Pair
TargetNucleotide-binding oligomerization domain-containing protein 2 (NOD2)(Human)
Odyssey Therapeutics
US Patent
Odyssey Therapeutics
US Patent
Affinity DataIC50: 0.300nMAssay Description:Compounds were added to a 384-well plate. Reaction mixtures contained 10 mM HEPES, pH 7.4, 10 mM MgCl2, 0.01% BSA, 0.0005% Tween 20, 1 mM ATP and 1 &...More data for this Ligand-Target Pair
TargetNucleotide-binding oligomerization domain-containing protein 2 (NOD2)(Human)
Odyssey Therapeutics
US Patent
Odyssey Therapeutics
US Patent
Affinity DataIC50: 0.300nMAssay Description:Biochemical JAK and Off-Target Kinase Assays. A panel of four LanthaScreen JAK biochemical assays (JAK1, 2, 3 and Tyk2) were carried in a common kin...More data for this Ligand-Target Pair
TargetNucleotide-binding oligomerization domain-containing protein 2 (NOD2)(Human)
Odyssey Therapeutics
US Patent
Odyssey Therapeutics
US Patent
Affinity DataIC50: 0.300nMAssay Description:Biochemical JAK and Off-Target Kinase Assays. A panel of four LanthaScreen JAK biochemical assays (JAK1, 2, 3 and Tyk2) were carried in a common kin...More data for this Ligand-Target Pair
TargetNucleotide-binding oligomerization domain-containing protein 2 (NOD2)(Human)
Odyssey Therapeutics
US Patent
Odyssey Therapeutics
US Patent
Affinity DataIC50: 0.300nMAssay Description:Compounds were added to a 384-well plate. Reaction mixtures contained 10 mM HEPES, pH 7.4, 10 mM MgCl2, 0.01% BSA, 0.0005% Tween 20, 1 mM ATP and 1 &...More data for this Ligand-Target Pair
TargetNucleotide-binding oligomerization domain-containing protein 2 (NOD2)(Human)
Odyssey Therapeutics
US Patent
Odyssey Therapeutics
US Patent
Affinity DataIC50: 0.300nMAssay Description:Biochemical JAK and Off-Target Kinase Assays. A panel of four LanthaScreen JAK biochemical assays (JAK1, 2, 3 and Tyk2) were carried in a common kin...More data for this Ligand-Target Pair
TargetNucleotide-binding oligomerization domain-containing protein 2 (NOD2)(Human)
Odyssey Therapeutics
US Patent
Odyssey Therapeutics
US Patent
Affinity DataIC50: 0.300nMAssay Description:Biochemical JAK and Off-Target Kinase Assays. A panel of four LanthaScreen JAK biochemical assays (JAK1, 2, 3 and Tyk2) were carried in a common kin...More data for this Ligand-Target Pair
TargetNucleotide-binding oligomerization domain-containing protein 2 (NOD2)(Human)
Odyssey Therapeutics
US Patent
Odyssey Therapeutics
US Patent
Affinity DataIC50: 0.300nMAssay Description:Biochemical JAK and Off-Target Kinase Assays. A panel of four LanthaScreen JAK biochemical assays (JAK1, 2, 3 and Tyk2) were carried in a common kin...More data for this Ligand-Target Pair
TargetNucleotide-binding oligomerization domain-containing protein 2 (NOD2)(Human)
Odyssey Therapeutics
US Patent
Odyssey Therapeutics
US Patent
Affinity DataIC50: 0.400nMAssay Description:Biochemical JAK and Off-Target Kinase Assays. A panel of four LanthaScreen JAK biochemical assays (JAK1, 2, 3 and Tyk2) were carried in a common kin...More data for this Ligand-Target Pair
TargetNucleotide-binding oligomerization domain-containing protein 2 (NOD2)(Human)
Odyssey Therapeutics
US Patent
Odyssey Therapeutics
US Patent
Affinity DataIC50: 0.400nMAssay Description:Biochemical JAK and Off-Target Kinase Assays. A panel of four LanthaScreen JAK biochemical assays (JAK1, 2, 3 and Tyk2) were carried in a common kin...More data for this Ligand-Target Pair
TargetNucleotide-binding oligomerization domain-containing protein 2 (NOD2)(Human)
Odyssey Therapeutics
US Patent
Odyssey Therapeutics
US Patent
Affinity DataIC50: 0.400nMAssay Description:Biochemical JAK and Off-Target Kinase Assays. A panel of four LanthaScreen JAK biochemical assays (JAK1, 2, 3 and Tyk2) were carried in a common kin...More data for this Ligand-Target Pair
TargetNucleotide-binding oligomerization domain-containing protein 2 (NOD2)(Human)
Odyssey Therapeutics
US Patent
Odyssey Therapeutics
US Patent
Affinity DataIC50: 0.400nMAssay Description:Biochemical JAK and Off-Target Kinase Assays. A panel of four LanthaScreen JAK biochemical assays (JAK1, 2, 3 and Tyk2) were carried in a common kin...More data for this Ligand-Target Pair
TargetNucleotide-binding oligomerization domain-containing protein 2 (NOD2)(Human)
Odyssey Therapeutics
US Patent
Odyssey Therapeutics
US Patent
Affinity DataIC50: 0.400nMAssay Description:Biochemical JAK and Off-Target Kinase Assays. A panel of four LanthaScreen JAK biochemical assays (JAK1, 2, 3 and Tyk2) were carried in a common kin...More data for this Ligand-Target Pair
TargetNucleotide-binding oligomerization domain-containing protein 2 (NOD2)(Human)
Odyssey Therapeutics
US Patent
Odyssey Therapeutics
US Patent
Affinity DataIC50: 0.5nMAssay Description:Compounds were added to a 384-well plate. Reaction mixtures contained 10 mM HEPES, pH 7.4, 10 mM MgCl2, 0.01% BSA, 0.0005% Tween 20, 1 mM ATP and 1 &...More data for this Ligand-Target Pair
TargetNucleotide-binding oligomerization domain-containing protein 2 (NOD2)(Human)
Odyssey Therapeutics
US Patent
Odyssey Therapeutics
US Patent
Affinity DataIC50: 0.5nMAssay Description:Compounds were added to a 384-well plate. Reaction mixtures contained 10 mM HEPES, pH 7.4, 10 mM MgCl2, 0.01% BSA, 0.0005% Tween 20, 1 mM ATP and 1 &...More data for this Ligand-Target Pair
TargetNucleotide-binding oligomerization domain-containing protein 2 (NOD2)(Human)
Odyssey Therapeutics
US Patent
Odyssey Therapeutics
US Patent
Affinity DataIC50: 0.5nMAssay Description:Biochemical JAK and Off-Target Kinase Assays. A panel of four LanthaScreen JAK biochemical assays (JAK1, 2, 3 and Tyk2) were carried in a common kin...More data for this Ligand-Target Pair
TargetNucleotide-binding oligomerization domain-containing protein 2 (NOD2)(Human)
Odyssey Therapeutics
US Patent
Odyssey Therapeutics
US Patent
Affinity DataIC50: 0.5nMAssay Description:Compounds were added to a 384-well plate. Reaction mixtures contained 10 mM HEPES, pH 7.4, 10 mM MgCl2, 0.01% BSA, 0.0005% Tween 20, 1 mM ATP and 1 &...More data for this Ligand-Target Pair
TargetNucleotide-binding oligomerization domain-containing protein 2 (NOD2)(Human)
Odyssey Therapeutics
US Patent
Odyssey Therapeutics
US Patent
Affinity DataIC50: 0.5nMAssay Description:Biochemical JAK and Off-Target Kinase Assays. A panel of four LanthaScreen JAK biochemical assays (JAK1, 2, 3 and Tyk2) were carried in a common kin...More data for this Ligand-Target Pair
TargetNucleotide-binding oligomerization domain-containing protein 2 (NOD2)(Human)
Odyssey Therapeutics
US Patent
Odyssey Therapeutics
US Patent
Affinity DataIC50: 0.5nMAssay Description:Biochemical JAK and Off-Target Kinase Assays. A panel of four LanthaScreen JAK biochemical assays (JAK1, 2, 3 and Tyk2) were carried in a common kin...More data for this Ligand-Target Pair
TargetNucleotide-binding oligomerization domain-containing protein 2 (NOD2)(Human)
Odyssey Therapeutics
US Patent
Odyssey Therapeutics
US Patent
Affinity DataIC50: 0.600nMAssay Description:Biochemical JAK and Off-Target Kinase Assays. A panel of four LanthaScreen JAK biochemical assays (JAK1, 2, 3 and Tyk2) were carried in a common kin...More data for this Ligand-Target Pair
TargetNucleotide-binding oligomerization domain-containing protein 2 (NOD2)(Human)
Odyssey Therapeutics
US Patent
Odyssey Therapeutics
US Patent
Affinity DataIC50: 0.600nMAssay Description:Biochemical JAK and Off-Target Kinase Assays. A panel of four LanthaScreen JAK biochemical assays (JAK1, 2, 3 and Tyk2) were carried in a common kin...More data for this Ligand-Target Pair
TargetNucleotide-binding oligomerization domain-containing protein 2 (NOD2)(Human)
Odyssey Therapeutics
US Patent
Odyssey Therapeutics
US Patent
Affinity DataIC50: 0.600nMAssay Description:Biochemical JAK and Off-Target Kinase Assays. A panel of four LanthaScreen JAK biochemical assays (JAK1, 2, 3 and Tyk2) were carried in a common kin...More data for this Ligand-Target Pair
TargetNucleotide-binding oligomerization domain-containing protein 2 (NOD2)(Human)
Odyssey Therapeutics
US Patent
Odyssey Therapeutics
US Patent
Affinity DataIC50: 0.600nMAssay Description:Biochemical JAK and Off-Target Kinase Assays. A panel of four LanthaScreen JAK biochemical assays (JAK1, 2, 3 and Tyk2) were carried in a common kin...More data for this Ligand-Target Pair
TargetNucleotide-binding oligomerization domain-containing protein 2 (NOD2)(Human)
Odyssey Therapeutics
US Patent
Odyssey Therapeutics
US Patent
Affinity DataIC50: 0.600nMAssay Description:Biochemical JAK and Off-Target Kinase Assays. A panel of four LanthaScreen JAK biochemical assays (JAK1, 2, 3 and Tyk2) were carried in a common kin...More data for this Ligand-Target Pair
TargetNucleotide-binding oligomerization domain-containing protein 2 (NOD2)(Human)
Odyssey Therapeutics
US Patent
Odyssey Therapeutics
US Patent
Affinity DataIC50: 0.700nMAssay Description:Compounds were added to a 384-well plate. Reaction mixtures contained 10 mM HEPES, pH 7.4, 10 mM MgCl2, 0.01% BSA, 0.0005% Tween 20, 1 mM ATP and 1 &...More data for this Ligand-Target Pair
TargetNucleotide-binding oligomerization domain-containing protein 2 (NOD2)(Human)
Odyssey Therapeutics
US Patent
Odyssey Therapeutics
US Patent
Affinity DataIC50: 0.700nMAssay Description:Biochemical JAK and Off-Target Kinase Assays. A panel of four LanthaScreen JAK biochemical assays (JAK1, 2, 3 and Tyk2) were carried in a common kin...More data for this Ligand-Target Pair
TargetNucleotide-binding oligomerization domain-containing protein 2 (NOD2)(Human)
Odyssey Therapeutics
US Patent
Odyssey Therapeutics
US Patent
Affinity DataIC50: 0.700nMAssay Description:Biochemical JAK and Off-Target Kinase Assays. A panel of four LanthaScreen JAK biochemical assays (JAK1, 2, 3 and Tyk2) were carried in a common kin...More data for this Ligand-Target Pair
TargetNucleotide-binding oligomerization domain-containing protein 2 (NOD2)(Human)
Odyssey Therapeutics
US Patent
Odyssey Therapeutics
US Patent
Affinity DataIC50: 0.700nMAssay Description:Biochemical JAK and Off-Target Kinase Assays. A panel of four LanthaScreen JAK biochemical assays (JAK1, 2, 3 and Tyk2) were carried in a common kin...More data for this Ligand-Target Pair
TargetNucleotide-binding oligomerization domain-containing protein 2 (NOD2)(Human)
Odyssey Therapeutics
US Patent
Odyssey Therapeutics
US Patent
Affinity DataIC50: 0.700nMAssay Description:Biochemical JAK and Off-Target Kinase Assays. A panel of four LanthaScreen JAK biochemical assays (JAK1, 2, 3 and Tyk2) were carried in a common kin...More data for this Ligand-Target Pair
TargetNucleotide-binding oligomerization domain-containing protein 2 (NOD2)(Human)
Odyssey Therapeutics
US Patent
Odyssey Therapeutics
US Patent
Affinity DataIC50: 0.700nMAssay Description:Biochemical JAK and Off-Target Kinase Assays. A panel of four LanthaScreen JAK biochemical assays (JAK1, 2, 3 and Tyk2) were carried in a common kin...More data for this Ligand-Target Pair
TargetNucleotide-binding oligomerization domain-containing protein 2 (NOD2)(Human)
Odyssey Therapeutics
US Patent
Odyssey Therapeutics
US Patent
Affinity DataIC50: 0.700nMAssay Description:Biochemical JAK and Off-Target Kinase Assays. A panel of four LanthaScreen JAK biochemical assays (JAK1, 2, 3 and Tyk2) were carried in a common kin...More data for this Ligand-Target Pair
TargetNucleotide-binding oligomerization domain-containing protein 2 (NOD2)(Human)
Odyssey Therapeutics
US Patent
Odyssey Therapeutics
US Patent
Affinity DataIC50: 0.700nMAssay Description:Biochemical JAK and Off-Target Kinase Assays. A panel of four LanthaScreen JAK biochemical assays (JAK1, 2, 3 and Tyk2) were carried in a common kin...More data for this Ligand-Target Pair
TargetNucleotide-binding oligomerization domain-containing protein 2 (NOD2)(Human)
Odyssey Therapeutics
US Patent
Odyssey Therapeutics
US Patent
Affinity DataIC50: 0.800nMAssay Description:Biochemical JAK and Off-Target Kinase Assays. A panel of four LanthaScreen JAK biochemical assays (JAK1, 2, 3 and Tyk2) were carried in a common kin...More data for this Ligand-Target Pair
TargetNucleotide-binding oligomerization domain-containing protein 2 (NOD2)(Human)
Odyssey Therapeutics
US Patent
Odyssey Therapeutics
US Patent
Affinity DataIC50: 0.800nMAssay Description:Biochemical JAK and Off-Target Kinase Assays. A panel of four LanthaScreen JAK biochemical assays (JAK1, 2, 3 and Tyk2) were carried in a common kin...More data for this Ligand-Target Pair

















































